{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:15:16Z","timestamp":1793128516354,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venous thromboembolism (VTE), including deep-vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in cancer patients. Patients with cancer are six times more likely to develop VTE than their noncancer counterparts, and VTE is the second leading cause of death in cancer patients. Despite the publication of major consensus guidelines setting out recommendations for thromboprophylaxis in cancer patients, there remains a gulf between these guidelines and clinical practice. In general, thromboprophylaxis is recommended for most patients hospitalized with active cancer. Furthermore, outpatient thromboprophylaxis may be used in carefully selected high-risk ambulatory patients. Certain areas of controversy still remain. Although low-molecular-weight heparin has been shown to be superior to vitamin K antagonists in cancer patients, the role of direct oral anticoagulants is still uncertain. Moreover, recurrent thromboembolism, bleeding, and thrombocytopenia are frequently seen in cancer patients. Optimal anticoagulation in such instances presents a major challenge to clinicians. Modern computed tomography techniques have resulted in an increase in the detection of \u201cincidental\u201d VTE. Despite a growing body of evidence promulgating standard anticoagulant treatment in such cases, these cases present further challenges for members of the multidisciplinary team.<\/jats:p>","DOI":"10.1634\/theoncologist.2016-0214","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T21:20:18Z","timestamp":1486502418000},"page":"199-207","source":"Crossref","is-referenced-by-count":227,"title":["Cancer and Venous Thromboembolic Disease: A Review"],"prefix":"10.1093","volume":"22","author":[{"given":"Eoin","family":"Donnellan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"2021122506434562700_onco12019-bib-0001","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1538-7836.2003.00501.x","article-title":"Malignancy, thrombosis and Trousseau: The case for an eponym","volume":"1","author":"Khorana","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"suppl 6","key":"2021122506434562700_onco12019-bib-0002","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"2021122506434562700_onco12019-bib-0003","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.18553\/jmcp.2005.11.8.663","article-title":"Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization","volume":"11","author":"Bullano","year":"2005","journal-title":"J Manag Care Pharm"},{"key":"2021122506434562700_onco12019-bib-0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.critrevonc.2007.01.001","article-title":"Cancer-associated thrombosis","volume":"62","author":"Zwicker","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122506434562700_onco12019-bib-0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3747\/co.21.1864","article-title":"Cancer and venous thromboembolic disease: From molecular mechanisms to clinical management","volume":"21","author":"Donnellan","year":"2014","journal-title":"Curr Oncol"},{"key":"2021122506434562700_onco12019-bib-0007","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/0008-5472.CAN-04-3376","article-title":"PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma","volume":"65","author":"Rong","year":"2005","journal-title":"Cancer Res"},{"key":"2021122506434562700_onco12019-bib-0008","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1373\/clinchem.2009.123695","article-title":"Increased tissue factor expression is associated with reduced survival in non\u2013small cell lung cancer and with mutations of TP53 and PTEN","volume":"55","author":"Regina","year":"2009","journal-title":"Clin Chem"},{"key":"2021122506434562700_onco12019-bib-0009","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1200\/JCO.2009.22.7199","article-title":"Genetic link between cancer and thrombosis","volume":"27","author":"Boccaccio","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0011","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"2021122506434562700_onco12019-bib-0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH06-07-0365","article-title":"Racial and gender differences in the incidence of recurrent venous thromboembolism","volume":"96","author":"White","year":"2006","journal-title":"Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0013","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"2021122506434562700_onco12019-bib-0014","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.thromres.2014.12.013","article-title":"Risk of site-specific cancer in incident venous thromboembolism: A population-based study","volume":"135","author":"Petterson","year":"2015","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"2021122506434562700_onco12019-bib-0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"Sallah","year":"2002","journal-title":"Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0017","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.thromres.2012.03.019","article-title":"Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population","volume":"130","author":"Park","year":"2012","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0018","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"2021122506434562700_onco12019-bib-0019","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0020","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"2021122506434562700_onco12019-bib-0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"2021122506434562700_onco12019-bib-0022","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0023","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0024","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0025","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","article-title":"Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer","volume":"168","author":"Khorana","year":"2008","journal-title":"Arch Intern Med"},{"key":"2021122506434562700_onco12019-bib-0026","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0027","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor\u2013bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122506434562700_onco12019-bib-0028","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"2021122506434562700_onco12019-bib-0029","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"Suppl 2","key":"2021122506434562700_onco12019-bib-0030","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","article-title":"Risk stratification strategies for cancer-associated thrombosis: An update","volume":"133","author":"Khorana","year":"2014","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0031","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0032","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.thromres.2015.08.002","article-title":"Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis","volume":"136","author":"Lustig","year":"2015","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0033","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.thromres.2014.09.016","article-title":"Screening high-risk cancer patients for VTE: A prospective observational study","volume":"134","author":"Khorana","year":"2014","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0034","author":"Khorana","year":"2015"},{"key":"2021122506434562700_onco12019-bib-0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2021122506434562700_onco12019-bib-0036","doi-asserted-by":"crossref","first-page":"206a","DOI":"10.1182\/blood.V118.21.206.206","article-title":"Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: Benefit-risk assessment by VTE risk in SAVE-ONCO","volume":"118","author":"George","year":"2011","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0037","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1538-7836.2007.02650.x","article-title":"Thromboprophylaxis rates in US medical centers: Success or failure?","volume":"5","author":"Amin","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"suppl 6","key":"2021122506434562700_onco12019-bib-0038","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2146\/ajhp060390","article-title":"Thromboprophylaxis in medically ill patients at risk for venous thromboembolism","volume":"63","author":"Burleigh","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"2021122506434562700_onco12019-bib-0039","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2006.01.011","article-title":"Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada","volume":"119","author":"Kahn","year":"2007","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0040","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1200\/JCO.2013.53.5336","article-title":"Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: A prospective, cross-sectional, multicenter study","volume":"32","author":"Zwicker","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"key":"2021122506434562700_onco12019-bib-0042","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0043","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"2021122506434562700_onco12019-bib-0044","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0045","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122506434562700_onco12019-bib-0046","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2407-8-361","article-title":"Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)","volume":"8","author":"Riess","year":"2008","journal-title":"BMC Cancer"},{"key":"2021122506434562700_onco12019-bib-0047","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0048","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1160\/TH03-03-0152","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0049","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archsurg.1992.01420030076014","article-title":"Postoperative pulmonary embolism after hospital discharge. An underestimated risk","volume":"127","author":"Huber","year":"1992","journal-title":"Arch Surg"},{"key":"2021122506434562700_onco12019-bib-0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann Surg"},{"key":"2021122506434562700_onco12019-bib-0051","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0052","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1538-7836.2006.02153.x","article-title":"Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study","volume":"4","author":"Rasmussen","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0053","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1538-7836.2006.02083.x","article-title":"A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer","volume":"4","author":"Simonneau","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0054","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta9490","article-title":"Towards evidence-based guidelines for the prevention of venous thromboembolism: Systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis","volume":"9","author":"Roderick","year":"2005","journal-title":"Health Technol Assess"},{"key":"2021122506434562700_onco12019-bib-0055","first-page":"101","article-title":"Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum, International Union of Angiology, Union Internationale de Phl\u00e9bologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)","volume":"25","author":"Cardiovascular Disease Educational and Research Trust","year":"2006","journal-title":"Int Angiol"},{"key":"2021122506434562700_onco12019-bib-0056","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0057","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1160\/TH11-01-0002","article-title":"Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II","volume":"105","author":"Spirk","year":"2011","journal-title":"Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0058","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.11458","article-title":"Clinical characteristics and management of cancer-associated acute venous thromboembolism: Findings from the MASTER Registry","volume":"93","author":"Imberti","year":"2008","journal-title":"Haematologica"},{"key":"2021122506434562700_onco12019-bib-0059","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-9966-27-21","article-title":"Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: A Cochrane systematic review","volume":"27","author":"Akl","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122506434562700_onco12019-bib-0061","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-13-284","article-title":"CATCH: A randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122506434562700_onco12019-bib-0062","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"2021122506434562700_onco12019-bib-0063","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021122506434562700_onco12019-bib-0064","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jth.12434","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: A rebuttal","volume":"12","author":"Oo","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0065","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/743181","article-title":"Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients","author":"Hohl Moinat","journal-title":"J Oncol"},{"key":"2021122506434562700_onco12019-bib-0066","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bmjspcare-2011-000166","article-title":"Management of cancer-associated thrombosis in people with advanced disease","volume":"2","author":"Noble","year":"2012","journal-title":"BMJ Support Palliat Care"},{"key":"2021122506434562700_onco12019-bib-0067","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2009.24.7346","article-title":"New antithrombotic drugs: potential for use in oncology","volume":"27","author":"Levine","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0068","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Agnelli","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0069","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122506434562700_onco12019-bib-0070","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: A systematic review and meta-analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0071","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.104.512834","article-title":"The PREPIC (Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave) Randomized Study","volume":"112","author":"Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism","year":"2005","journal-title":"Circulation"},{"key":"2021122506434562700_onco12019-bib-0072","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/COC.0b013e318248da32","article-title":"Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer","volume":"36","author":"Matsuo","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0073","first-page":"S172","article-title":"Cancer-associated unsuspected pulmonary embolism","author":"Es","year":"2014","journal-title":"Thromb Res"},{"key":"2021122506434562700_onco12019-bib-0074","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.11.015","article-title":"Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy","volume":"69","author":"Sun","year":"2010","journal-title":"Lung Cancer"},{"key":"2021122506434562700_onco12019-bib-0075","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: A comparison with symptomatic patients","volume":"29","author":"den Exter","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122506434562700_onco12019-bib-0076","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0077","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1538-7836.2010.04114.x","article-title":"Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning","volume":"9","author":"O\u2019Connell","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0078","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: Guidance from the SSC of the ISTH","volume":"13","author":"Nisio","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2021122506434562700_onco12019-bib-0079","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V124.21.590.590","article-title":"Risk of recurrent venous thromboembolism and major bleeding in cancer-associated incidental pulmonary embolism amongst treated and untreated patients: A pooled analysis of 926 patients","volume":"124","author":"Hulle","year":"2014","journal-title":"Blood"},{"key":"2021122506434562700_onco12019-bib-0080","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.thromres.2010.07.001","article-title":"Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography","volume":"126","author":"Donato","year":"2010","journal-title":"Thromb Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/199\/41913550\/oncolo_22_2_199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/199\/41913550\/oncolo_22_2_199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T01:46:14Z","timestamp":1640396774000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/2\/199\/6438570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":80,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0214","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2017,2,1]]}}}